AUS
NZ
UK
CA
USA
IND
Highlights:
- Psyence Group agrees to a debt-for-equity swap with Psyence Biomedical.
- The Company will receive over 2 million common shares at a deemed price of $0.50.
- The move aims to enhance liquidity and improve portfolio flexibility.
Psyence Group Inc (CSE: PSYG) has announced a strategic debt-for-equity swap agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ:PBM). Under this agreement, Psyence Biomedical will issue 2,075,920 common shares to Psyence Group at a deemed price of $0.50 per share. In return, Psyence Group will discharge a portion of the debt repayment obligation due under a promissory note that was issued in January 2024. This transaction is seen as a key step in enhancing the Company's financial flexibility and liquidity.
The Debt Swap comes as part of Psyence Biomedical's ongoing efforts to solidify its position in the market since its NASDAQ listing earlier this year. As part of the agreement, if the average volume-weighted average price (VWAP) of Psyence Biomedical's shares falls below $0.50 in the ten trading days leading up to January 15, 2025, the Company will be entitled to a "make whole payment" either in cash or additional common shares. This provision ensures that Psyence Group has a level of protection against potential declines in share price.
Executive Chairman Jody Aufrichtig emphasized the significance of the Debt Swap, stating, "The Debt Swap allows the Company to improve its overall portfolio flexibility by acquiring readily tradable securities and enhancing liquidity. The acquisition of the publicly traded shares of PBM provides greater transparency and market valuation, helping to establish a clearer assessment of the investment's worth." This move reflects Psyence Group's proactive approach to managing its financial obligations while positioning itself for future growth.
The Debt Swap Agreement also includes customary representations, warranties, and covenants between the parties involved. It qualifies as a "related party transaction" under Multilateral Instrument 61-101, which aims to protect minority security holders in special transactions. Psyence Group is relying on exemptions from the formal valuation and minority shareholder approval requirements of this instrument. This is based on the determination that the fair market value of the loan amount discharged and the consideration received will not exceed 25% of the Company’s market capitalization at the time the agreement was reached.
Psyence Group’s board of directors has approved the Debt Swap Agreement, with appropriate recusal of interested directors who also serve on Psyence Biomedical's board. Importantly, no contrary opinions or abstentions were expressed by any director regarding the transaction. To expedite the process, the Company has chosen not to file a material change report in advance of the anticipated closing, aiming for a swift resolution to capitalize on the benefits this agreement presents.
In summary, this debt-for-equity swap marks a significant development for Psyence Group, enhancing its liquidity and positioning it for a more favorable market valuation as it continues to navigate the complexities of the precious metals and biotechnology sectors.
